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A B S T R A C T
Patients with inherited bone marrow failure syndromes (IBMFS), such as Fanconi anemia (FA), dyskeratosis
congenita (DC), or Diamond Blackfan anemia (DBA), can have hematologic manifestations cured through he-
matopoietic cell transplantation (HCT). Subsequent late effects seen in these patients arise from a combination
of the underlying disease, the pre-HCT therapy, and the HCT process. During the international consensus con-
ference sponsored by the Pediatric Blood and Marrow Transplant Consortium on late effects screening and
recommendations following allogeneic hematopoietic cell transplantation for immune deficiency and non-
malignant hematologic diseases held in Minneapolis, Minnesota in May 2016, a half-day session was focused
specifically on the unmet needs for these patients with IBMFS. This multidisciplinary group of experts in rare
diseases and transplantation late effects has already published on the state of the science in this area, along
with discussion of an agenda for future research. This companion article outlines consensus disease-specific
long-term follow-up screening guidelines for patients with IMBFS.
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Increasing indications for allogeneic hematopoietic cell
transplantation (HCT) in childhood diseases [1-3] and im-
proved survival post-HCT lead to the projection that there will
be more than 70,000 childhood HCT survivors under age 18
years at transplantation by 2030 in the United States alone
[1]. Children undergoing HCT for nonmalignant diseases, in-
cluding inherited bone marrow failure syndromes (IBMFS),
immune system disorders, and hemoglobinopathies, repre-
sent a growing number of patients with special follow-up
needs [4].
Much of our understanding of long-term toxicities in sur-
vivors of pediatric HCT comes from the study of patients with
hematologic malignancies. These patients have a high burden
of late effects and mortality compared with the general pop-
ulation [5], as well as compared childhood cancer survivors
treated with chemotherapy and/or radiation. Known risk
factors include younger age at HCT, conditioning with total
body irradiation (TBI), and chronic graft-versus-host disease
(GVHD) [6-14]. Recent reports have examined populations
with much larger proportions of nonmalignant HCT survi-
vors [15]. Numerous single-center and smaller consortia
reports have shown that long-term complications are common
in survivors of transplantation for IBMFS, hemoglobinopa-
thies, and immune deficiencies [16-27].
General HCT follow-up guidelines have been published
[28-31] and reviewed [32], as summarized in Table 1; however,
these guidelines do not consider pretransplantation expo-
sures or disease-specific manifestations that are unique
to patients with nonmalignant hematopoietic disorders,
and cannot be readily interchanged with exposures for
malignant diseases, such as chemotherapy and radiation. Fur-
thermore, the interaction of each specific nonmalignant
disorder with the HCT process may alter the natural history
Table 1
General Late Effects Screening Guidelines after Hematopoietic Cell Transplantation
Late Effect/Organ System Summary of General HCT Late Effects Guidelines
Immune reconstitution/
immunologic
• Patients with GVHD on immune suppression
• Encapsulated organism and pneumocystis antibiotic prophylaxis
• Broad-spectrum parenteral antibiotics for fevers
• Regular screening for CMV and/or other opportunistic infections
• Endocarditis prophylaxis according to AHA guidelines
• Annual evaluations for recurrent, unusual, or severe infections
• Screening for HIV and hepatitis in those exposed to blood products
• Immunizations according to published guidelines
• Monitoring of T cell and B cell immune reconstitution
• Monitoring of T cell proliferative capacity to mitogens
• Neoantigen challenge for patients with poor immune reconstitution
Iron overload • Serum ferritin screening post-HCT, repeat annually or as needed until normal
• Consider T2*-weighted MRI if screen is positive or significant transfusion history
• Follow LFTs regularly and consider hepatology consult if elevated
• Phlebotomy or chelation therapy for management if iron burden clinically significant
Neurocognitive • Yearly screening for educational and developmental progress
• Neuropsychological evaluation at minimum one year post-HCT, repeat as needed
• Referral to appropriate school or other resources for those with identified neurocognitive deficits
Subsequent cancer risk • Lifestyle counseling to avoid high-risk behaviors and encourage good behaviors (eg, smoking, excessive alcohol, sunscreen
use, healthy diet, exercise)
• Annual history and physical
• Encourage self-exam (eg, skin, oral cavity, genitalia)
• Follow general population cancer screening guidelines
• Regular dental exams for those with chronic GVHD
• Mammography in women beginning at age 25 or 8 years after TBI or chest radiation exposure (no later than age 40), with
consideration for breast MRI in some patients
Pulmonary • Annual history and physical
• Counsel regarding tobacco avoidance or cessation
• PFT every 6 to 12 months initially, then as clinically indicated
• Focused radiological exam for those with abnormal findings
• Referral to pulmonologist with abnormal findings
Reproductive/gonadal • At least annual assessment of pubertal development and sexual and reproductive function
• LH, FSH, and testosterone in males, consider semen analysis
• LH, FSH, and estradiol in females, with some centers using AMH screening
• Referral to endocrinologist, gynecologist, or urologist with abnormal pubertal timing or gonadal dysfunction
• Treat ovarian failure with hormone replacement therapy
• Counsel about birth control in those of reproductive age
Renal • At least annual hypertension screening
• At least annual urinalysis, urine protein or albumin to creatinine ratio, serum creatinine, and BUN
• Referral to nephrologist if hypertension or renal dysfunction
Growth • At least annual height, weight, BMI, and Tanner staging
• Annual thyroid function, bone age, and refer to endocrinologist for abnormal growth rate or other abnormalities
Psychosocial • At least annual assessment for mental health concerns, chronic pain and fatigue, risky behaviors, and access to health care
• Encouragement of robust support networks
• Additional assessment of family members and caregivers
• Referral to mental health professional as needed
HCT indicates hematopoietic cell transplantation; GVHD, graft-versus-host disease; CMV, cytomegalovirus; AHA, American Heart Association; HIV, human
immunodeficiency virus; MRI, magnetic resonance imaging; LFTs, liver function tests; TBI, total body irradiation; PFT, pulmonary function testing; LH, lutein
hormone; FSH, follicle-stimulating hormone; AMH, anti-mullerian hormone; BUN, blood urea nitrogen; BMI, body mass index.
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and risk of late effects. This is important for understanding
how to screen, diagnose, and treat or prevent these compli-
cations. These issues were discussed at the Second International
Pediatric Blood and Marrow Transplant Consortium Consensus
Conference on Late Effects after Pediatric Hematopoietic
Cell Transplantation in Minneapolis in May, 2016. The current
state of knowledge, as well as an agenda for future research
specific to IBMFS, has been published by this group [33],
and is summarized here in support of the surveillance
recommendations.
Table 1 presents a starting point for these new long-
term follow-up recommendations tailored to each individual
IBMFS. The consensus recommendations provided are meant
to outline an ideal follow-up approach from which to move
forward. It also should be noted that data on long-term follow-
up post-HCT for these disorders are limited, making it difficult
to create evidence-based guidelines for the management of
IBMFS. Thus, this work is based on a combination of avail-
able data and expert opinion. Moreover, gene therapy is not
addressed in these recommendations; however, because gene
therapy is used as a therapeutic modality for these chil-
dren, different approaches to follow-up may be needed. An
important area of consideration for all genetic diseases in-
cludes the need for genetic counseling, family planning, and
counseling regarding living with chronic conditions.
Of note, within the broad diagnostic categories of Fanconi
anemia (FA), dyskeratosis congenita (DC), and Diamond
Blackfan anemia (DBA) are a myriad of causative pathogen-
ic germline variants in multiple genes, many conferring very
specific phenotypes. This variability may have a bearing on
transplantation-related morbidity and mortality as well as
late effects in survivors. Although it is beyond the scope of
these guidelines, a detailed assessment of each patient keeping
this in mind is essential. This has been outlined in detail for
patients with FA (http://fanconi.org/index.php/publications/
guidelines_for_diagnosis_and_management) and DC (https://
www.dcoutreach.org/guidelines) in previously published
clinical guidelines.
FA
Five-year survival after a matched sibling HCT for FA is now
approximately 90%, with similar improvements after alter-
native donor HCT [24,34-37]. Many patients with FA are now
surviving to adulthood after undergoing HCT, and long-
term side effects of HCT are becoming more apparent. FA is
the most widely studied IBMFS to date with respect to late
effects after HCT. The follow-up of patients with FA who un-
derwent HCT may differ from the follow-up of patients
who underwent HCT for other indications and from the man-
agement of patients with FA who did not undergo HCT
with regard to nonhematologic systems, such as endocrine
manifestations and cancer risk. Table 2 summarizes the rec-
ommended screening guidelines for FA-specific late effects.
The wide variety of FA-related complications, including
those related to congenital anomalies, indicates the need for
close attention to these problems before, during, and long after
HCT. This can include neurodevelopmental issues as well as
genitourinary, renal, cardiac, gastrointestinal, and musculo-
skeletal anomalies [38,39]. Patients with FA who progressed
to severe marrow failure may have been treated previously
with transfusion support. Multiple red blood cell transfu-
sions without adequate iron chelation may lead to iron
Table 2
Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Fanconi Anemia
Late Effect/Organ System Fanconi Anemia Specific Guidelines
Immune reconstitution/immunologic • Ensure HPV vaccination
Iron overload • Earlier and more aggressive evaluation and management starting at 6 months post-HCT
Neurocognitive • Attention to FA-associated neurodevelopmental issues
Subsequent cancer risk • Dermatology: skin cancer screening every 6-12 months
• Monthly oral self exam, dental exam every 6 months, and ENT evaluation every 6-12 months by head and
neck physician, including nasolaryngoscopy (more frequent if unable to do self exam)
• Increased screening for SCC in those with chronic GVHD and in those with BRCA2 gene mutations,
specifically to look for medulloblastoma and Wilms tumor
Pulmonary • Follow-up as needed
Reproductive/gonadal • Follow-up of congenital genitourinary anomalies with a urologist
• Yearly gynecologic evaluation for females with Pap smear and HPV screening, starting in the early teenage
years
• Measure serum AMH as a potential early marker of gonadal insufficiency, with consideration for fertility
preservation measures
Renal • Follow-up congenital renal anomalies and renal function with a nephrologist
Growth • Full endocrine evaluation including GH levels (potentially with stimulation testing), IGF1, IGFBP3, Tanner
staging and bone age
• Monitor weight and assess for FA-associated failure to thrive
Psychosocial • Inclusion of genetic counseling for patient and family
• Assistance with family planning
• Counseling about living with chronic conditions
Cardiac • Follow up with cardiology for congenital cardiac anomalies and screen with ECG and Echocardiogram
Endocrine • Screening for diabetes, dyslipidemia, and Vitamin D deficiency
• Screening for osteoporosis with DEXA pre-HCT and every 2 years post-HCT
• Screening for avascular necrosis if bone or joint pain develop
Other • Screening for vision and cataracts
• Screening for hearing loss if clinically indicated
• Follow LFT regularly and consider hepatology consult if elevated
• Follow-up of congenital musculoskeletal anomalies and evaluation for scoliosis
• Lifestyle counseling to promote good health habits: encourage healthy diet and regular exercise, avoid
alcohol, smoking, and second-hand smoke, limit sun exposure and use sunscreen
HPV indicates human papilloma virus; HCT, hematopoietic cell transplantation; ENT, ears, nose, and throat physician; SCC, squamous cell carcinoma; GVHD,
graft-versus-host disease; AMH, anti-mullerian hormone; GH, growth hormone; IGF1, insulin-like growth factor 1; IGFBP3, insulin-like growth factor binding
protein 3; ECG, electrocardiogram; DEXA, dual-energy x-ray absorptiometry; LFT, liver function tests.
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overload in the liver, heart, and endocrine organs. Timely and
aggressive screening and management for iron overload are
recommended.
Endocrinopathies, including thyroid dysfunction, growth
hormone deficiency, glucose intolerance, and gonadal dys-
function, are common in patients with FA independent of
HCT, and can be exacerbated in the post-HCT period [40-43].
Routine and comprehensive follow-up with an endocrinol-
ogy team is strongly recommended and remains a key area
of post-HCT follow-up care.
The risk of acute myelogenous leukemia (AML) and my-
elodysplasia (MDS) is markedly decreased by HCT, whereas
solid tumors, most notably squamous cell carcinoma (SCC)
of head and neck and genital region, remain the most common
malignancies [44]. Oral cavity SCC in patients with FA is not
associated with human papillomavirus (HPV) in the same way
as oropharyngeal SCC is in the general population [45];
however, HPV vaccination is still recommended for preven-
tion of HPV-associated genital SCC regardless of sex. Although
chronic GVHD involving the mouth and/or genitourinary tract
has a strong association with the risk of SCC, the impact of
radiation is less clear but remains a possible risk factor
[23,24,46-50]. Whether busulfan or lowering the total dose
and dose rates of radiation or shielding has affected the risk
of cancer remains to be determined. Importantly, patients
whose FA is due to mutations in FANCD1/BRCA2 or FANCN/
PALB2 need genotype-specific cancer screening because of
increased risks of medulloblastoma, Wilms tumor, and other
cancers [51-54].
The long-term follow-up issue that merits the great-
est degree of attention in patients with FA post-HCT is the
apparent increased risk of cancer[55]. The importance of
screening for these cancers is increasingly recognized by
the development of specifically designed surveillance
schedules.
DC
Survival for patients with DC after HCT has not reached
the level of that for patients with FA, but there have been sig-
nificant improvements over time [56], such that more patients
with DC are living much longer after HCT. In contrast to FA,
DC-associated bone marrow failure develops more gradual-
ly, with a cumulative incidence of 40% by approximately age
40 [48], and thus patients with DC may be older than those
with FA when they undergo HCT. Although long-term events,
whether disease-related and/or late effects after HCT, are be-
coming more apparent, data on long-term follow-up after HCT
in this population are limited. There are important differ-
ences in HCT follow-up practices compared with otherwise
standard HCT follow-up with respect to nonhematologic mani-
festations of DC and cancer risk. Table 3 summarizes the
recommended DC-specific late effects screening guidelines.
Given the wide variety of DC-related complications, in-
cluding progression of the clinical manifestations, careful
attention to these problems is needed before, during, and long
after HCT. These include neurodevelopmental issues as well
as genitourinary anomalies and visual problems [39,57,58]. Life-
threatening issues include pulmonary fibrosis, liver cirrhosis,
enteropathy, gastrointestinal bleeding, and pulmonary arte-
riovenous malformations [39,57,58]. Patients with DC who
progressed to severe marrow failure may have been treated
previously with transfusion support, and multiple transfu-
sions may lead to iron overload in the liver, heart, and endocrine
organs. Thus, early and aggressive screening and management
Table 3
Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Dyskeratosis Congenita
Late Effect/Organ System Dyskeratosis Congenita Specific Guidelines
Immune reconstitution/immunologic • Ensure HPV vaccination
Iron overload • Earlier and more aggressive evaluation and management starting at 6 months post-HCT
Neurocognitive • Attention to DC-associated neurodevelopmental issues, particularly in those with HH or Revesz syndromes
Subsequent cancer risk • Dermatology for skin cancer screening every 6-12 months
• Monthly self oral exam, dental exam every 6 months, and ENT evaluation yearly by head and neck physician,
including nasolaryngoscopy (more frequent if unable to do self exam)
Pulmonary • Lifelong pulmonary symptom screening for DC-associated pulmonary fibrosis and other post-HCT issues
• PFT screening yearly with low threshold for referral to pulmonologist for decline in lung function
• Surveillance for pulmonary AVM with low threshold for bubble echo prior to HCT as well as in long-term
follow-up depending on pre-HCT results and symptoms
Gastrointestinal • Screening for esophageal stenosis with treatment as needed
• Surveillance for bleeding, ulceration, telangiectasias, and varices as clinically indicated
• Follow LFTs regularly and consider hepatology consult if elevated for DC-associated liver cirrhosis and
fibrosis
Reproductive/gonadal • Follow-up of congenital genitourinary anomalies with a urologist
• Examination for urethral stenosis, which may need dilation
• Yearly gynecologic evaluation for females with Pap smear and HPV screening
Renal • Follow-up as needed for congenital genitourinary anomalies and related renal dysfunction if present
Growth • Full endocrine evaluation including GH levels (potentially with stimulation testing), IGF1, IGFBP3, Tanner
staging, and bone age
• Measure weight and assess for DC-associated failure to thrive
Psychosocial • Inclusion of genetic counseling for patient and family
• Assistance with family planning
• Counseling about living with chronic conditions
Other • Screening for vision, lacrimal duct stenosis, retinal pathology, and cataracts
• Screening for hearing loss
• Lifestyle counseling to promote good health habits: encourage healthy diet and regular exercise, avoid
alcohol, smoking, and second-hand smoke, limit sun exposure and use sunscreen
• Screening for osteoporosis with DEXA pre-HCT and every 2 years post-HCT
• Evaluate for avascular necrosis if bone or joint pain develop
HPV indicates human papilloma virus; HCT, hematopoietic cell transplantation; HH, Hoyeraal-Hreidarsson; ENT, ears, nose, and throat physician; GVHD, graft-
versus-host disease; PFT, pulmonary function testing; AVM, arteriovenous malformation; LFTs, liver function tests; GH, growth hormone; IGF1, insulin-like
growth factor 1; IGFBP3, insulin-like growth factor binding protein 3; DEXA, dual-energy x-ray absorptiometry.
1425A.C. Dietz et al. / Biol Blood Marrow Transplant 23 (2017) 1422–1428
for iron overload are imortant. A comprehensive review of case
reports and case series has identified the major late adverse
events as pulmonary disease, liver disease, and vascular com-
plications. These complications differ from infection, graft failure,
and hemorrhage, the most common early causes of mortality
after HCT in other contexts [56]. Surveillance and timely in-
tervention for these late deadly complications are important,
given the reports of successful lung and liver transplantation
in patients with DC [59,60]. Osteoporosis and osteopenia are
commonly associated with DC [57] and can worsen after HCT
from the use of steroids. Surveillance for and optimization
of bone health after HCT also may help reduce avascular ne-
crosis of the hips and shoulders, which in severe cases may
necessitate joint replacement surgery at a young age.
The risks of AML and MDS are markedly decreased by HCT,
and thus solid tumors, most notably SCC of the head and neck
and genital region, remain the most common malignancies
[48,57,61]. There are very little data on the association between
HPV and oral cavity SCC in DC, although notably, one study
of head and neck SCC in 4 patients with DC did not detect HPV
in the tumors [45]. However, HPV vaccination is recom-
mended for prevention of HPV-associated genital SCC
regardless of sex. Similarly, close follow-up with dermatolo-
gy is an integral part of post-HCT care owing to the increased
risk of skin SCC.
The long-term follow-up issues that may occur with
aging but merit the greatest degree of attention in pa-
tients with DC post-HCT are pulmonary fibrosis, liver
fibrosis, pulmonary arteriovenous malformation, gastro-
intestinal bleeding, and increased risk of SCC.
DBA
Increasing numbers of patients are undergoing HCT for the
anemia of DBA with improved survival [62-64], and thus
long-term events, whether disease-related and/or late effects
after HCT, are becoming more apparent. There are little data
on long-term follow-up after HCT in this population. There
are some important differences in HCT follow-up in these pa-
tients compared with otherwise standard HCT follow-up with
respect to nonhematologic manifestations of DBA and cancer
risk. Table 4 summarizes the recommended screening guide-
lines for DBA-specific late effects.
The wide variety of DBA-related complications, including
craniofacial, cardiac, genitourinary, renal, and musculoskel-
etal anomalies [65,66], calls for multiple subspecialty care
teams throughout the entire pre-HCT and post-HCT period. The
other major issues faced by patients with DBA throughout the
transplantation process and into longer-term follow-up are
related to a previous history of regular transfusions and long-
term corticosteroid use. Significant endocrinopathies, including
problems with bone health are of particular concern [66,67].
The impact of iron burden specifically presents one of the major
challenges for patients with DBA and the importance of ad-
dressing this challenge before HCT cannot be overemphasized
[68]. Iron abatement via chelation must be addressed before
HCT with additional post-HCT phlebotomy or chelation to
prevent cardiac or hepatic complications.
The risks of AML and MDS are markedly decreased by HCT,
but solid tumors, most notably luminal gastrointestinal cancers
and osteosarcoma, remain the most common malignancies in
patients with DBA [69,70]. Individualized cancer screening prac-
tices need to evolve with recognition of these risks and better
understanding of the additional effects of HCT on the risk of
developing these and other cancers. In addition, it should be
noted that reduced-intensity HCT with partial chimerism may
not fully mitigate the risk of AML and MDS.
The long-term follow-up issues that merit the great-
est attention in patients with DBA post-HCT are iron
Table 4
Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Diamond Blackfan Anemia
Late Effect/Organ System Diamond Blackfan Anemia Specific Guidelines
Immune reconstitution/ immunologic • Ensure HPV vaccination
Iron overload • Likely to be one of the major issues both pre- and post-HCT, with need for the earliest and most aggressive
evaluation and management pre- and post-HCT
• T2*-weighted MRI (for both hepatic and cardiac iron load) in addition to ferritin yearly until iron overload is
resolved
• Follow LFTs regularly and consider hepatology consult if elevated
• Phlebotomy or chelation therapy as appropriate for management
Endocrine • Complete endocrine evaluation is necessary as any/all endocrine organs can have organ dysfunction
(thyroid, parathyroid, pancreatic, adrenal, gonadal, hypothalamic and pituitary) from iron overload
Neurocognitive • Attention to neurodevelopmental issues, particularly in those patients with craniofacial abnormalities and
large ribosomal protein gene deletions
Subsequent cancer risk • Surveillance strategies for luminal GI cancers, osteosarcoma, and others are being developed for these
patients and will apply post-HCT as well
Pulmonary • Follow-up as needed
Reproductive/gonadal • Follow-up of congenital genitourinary anomalies with a urologist and full endocrine evaluation mentioned
above
Renal • Follow-up congenital renal anomalies with a nephrologist
Growth • Full endocrine evaluation including GH levels (potentially with stimulation testing), IGF1, IGFBP3, Tanner
staging, and bone age
Psychosocial • Inclusion of genetic counseling for patient and family
• Assistance with family planning
• Counseling about living with chronic conditions
Other • Screening for vision and cataracts (especially with pre-HCT steroid use)
• Follow congenital cardiac anomalies and screen with ECG and Echocardiogram in addition to T2*-weighted
MRI mentioned above
• Follow-up of all congenital anomalies
• Lifestyle counseling to promote good health habits: encourage healthy diet and regular exercise, avoid
alcohol, smoking, and second-hand smoke, limit sun exposure and use sunscreen
HPV indicates human papilloma virus; HCT, hematopoietic cell transplantation; MRI, magnetic resonance imaging; LFTs, liver function tests; GI, gastrointes-
tinal; GH, growth hormone; IGF1, insulin-like growth factor 1; IGFBP3, insulin-like growth factor binding protein 3; ECG, electrocardiogram.
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overload, much of which is carried over from pre-HCT
treatment, and the increasing risk of solid tumors with
aging.
CONCLUSION
This report presents late effects screening guideline rec-
ommendations for patients with IBMFS post-HCT that have
been developed through an international collaboration and
consensus process. These recommendations are meant to
outline an ideal follow-up as a starting point for manage-
ment of these patients moving forward. With consistency in
follow-up and continued observation of these patients post-
HCT, we hope to learn additional information that will lead
to modification of these guidelines over time. These recom-
mendations focus on FA, DC, and DBA, but it is important to
understand and develop syndrome-specific guidelines for all
patients who undergo HCT for nonmalignant disease.
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